Cipla Ltd
Cipla Ltd (CIPLA) last traded at ₹1,418, a market capitalisation of ₹1,14,537 crore, on a P/E of 32.0. Over the past 52 weeks the stock has ranged between ₹1,166 and ₹1,673. Cipla Ltd last reported results for the quarter ended Jun 2026, with sales of ₹7,119 crore and net profit of ₹786 crore. Figures are as of 25 Aug 2026 and are not real time.
Cipla Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Cipla Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹7,119 cr, up 2.3% from ₹6,957 cr a year earlier. Net profit was ₹786 cr, down 39.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 |
| Expenses | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 |
| Operating profit | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 |
| OPM % | 27% | 28% | 23% | 26% | 25% | 18% | 15% | 17% |
| Other income | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 |
| Interest | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 |
| Depreciation | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 |
| Profit before tax | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 |
| Tax % | 27% | 17% | 19% | 27% | 27% | 24% | 22% | 27% |
| Net profit | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| EPS (₹) | 16.13 | 19.45 | 15.13 | 16.06 | 16.73 | 8.37 | 6.87 | 9.77 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Cipla Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 | 28,324 |
| Operating profit | 4,252 | 4,553 | 5,027 | 6,291 | 7,128 | 5,883 | 5,297 |
| OPM % | 22% | 21% | 22% | 24% | 26% | 21% | 19% |
| Net profit | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 | 3,356 |
| EPS (₹) | 29.82 | 31.19 | 34.71 | 51.05 | 65.28 | 48.02 | 41.74 |
TTM is the trailing twelve months to the most recent quarter.
Cipla Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 8%
- 3 Years
- 7%
- TTM
- 2%
- 10 Years
- 11%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- -34%
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 6%
- 1 Year
- -10%
- 10 Years
- 13%
- 5 Years
- 14%
- 3 Years
- 15%
- Last Year
- 12%
Cipla Ltd shareholding pattern
Promoters held 29.22% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.20% and DIIs 34.35%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 30.93% | 29.19% | 29.20% | 29.19% | 29.22% | 29.22% | 29.22% | 29.22% |
| FIIs | 28.80% | 26.65% | 26.28% | 25.24% | 24.54% | 23.93% | 22.55% | 20.20% |
| DIIs | 23.95% | 27.49% | 27.89% | 28.98% | 29.98% | 30.45% | 31.71% | 34.35% |
| Government | 0.21% | 0.23% | 0.26% | 0.27% | 0.27% | 0.27% | 0.27% | 0.28% |
| Public | 16.11% | 16.43% | 16.36% | 16.30% | 15.99% | 16.12% | 16.26% | 15.93% |
| No. of shareholders | 4,70,234 | 5,25,114 | 5,43,420 | 5,49,655 | 5,34,587 | 5,40,521 | 5,84,217 | 5,78,679 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cipla Ltd corporate filings
- USFDA Inspection At Company'S Manufacturing Facility In Pithampur, IndiaCompany Updatelow impact
Cruxal's analysis: Cipla Ltd has formally disclosed that the US Food and Drug Administration (USFDA) is…
Read the full analysis - Cipla has informed the exchange about receipt of order from Hon''ble NCLT, Mumbai BenchCompany Updatelow impact
Cruxal's analysis: Cipla Limited has received approval from the National Company Law Tribunal (NCLT) for the…
Read the full analysis - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Cipla Ltd has submitted a disclosure regarding its ESG ratings as part of its routine…
Read the full analysis - Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USACompany Updatelow impact
Cruxal's analysis: Cipla Ltd. has issued an intimation regarding the USFDA inspection at its Invagen…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Cipla Ltd
Cruxal reads every Cipla Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.